Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy
Dr. John Cush @RheumNow( View Tweet )
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush @RheumNow( View Tweet )
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
Dr. John Cush @RheumNow( View Tweet )
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Read Article
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush @RheumNow( View Tweet )
Damage in Childhood Lupus
EurekAlert!
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise. The EULAR/ACR-2019 criteria have shown sensitivity in cSLE patients, which could allow earlier
Read Article
#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
New #JAKi #disease #results
#Baricitinib in #alopecia #areata esp 4mg/d
#Upadacitinib in Crohn’s
#Upa in #polyarticular #JIA & kid #PsA
+RCT of UPA in #GCA
Awaiting results of #SLE
With #deucravicitinib & UPA #RCTs
#EULAR2024 @eular_org @RheumNow
Janet Pope @Janetbirdope( View Tweet )
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz
Dr. John Cush @RheumNow( View Tweet )
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Read Article
Systemic sclerosis sine scleroderma in children is more aggressive than in adults. 18 juvenile vs 38 adults - ssJSSc more female (39% vs 89%), more digital pitting scars/ulcers (35 vs 10.5%), Pulm (50 vs 24) & CV (50 vs 3%); w/ more deaths https://t.co/l4f5bH1IX1 https://t.co/viQcD3tN9V
Dr. John Cush @RheumNow( View Tweet )
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari); Good improvement in 90%, 69% & 93%, respectively. JAK indication refractory skin dz (35%) or muscle involvement (29%). TIME FOR RCTs!! https://t.co/Vtm2n9BWV1 https://t.co/1bXZokW1AO
Links:
Dr. John Cush @RheumNow( View Tweet )
Pharmacologic Efficacy in Still's Disease
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
A metanalysis was performed using databases, trial
Cutoffs for Systemic Juvenile Arthritis Disease Activity Score
An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10), a disease activity measure distinguish patients with inactive disease, minimal disease activity, moderate disease
Read Article
Featured BSR Abstracts (5.2.2024)
Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.
Read Article
Methotrexate Does Not Increase ILD Risk in Dermatomyositis
A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).
ILD affects ~23% of DM patients and the oft used MTX is has a low risk of pneumonitis and pulmonary
Read Article
Rheum Chapter Notes (4.26.2024)
Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.
Read Article
Pediatric IMID pts have 4 fold mortality. Danish population study of 11,581 pIMID (vs 99K controls), 1.37 million PYs F/U. Dx age 12.6 yrs; 152 pIMID deaths (vs 316) aHR=3.8. +6.9 deaths/100K PYs. Most for GI Dz/CA & lymphoproliferative dz https://t.co/JpGzusLXMH https://t.co/OMtB1z0RmG
Dr. John Cush @RheumNow( View Tweet )
Canary in a Coal Mine (4.19.2024)
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read Article
Mental health in 1150 adolescents & young adults w/ juvenile idiopathic arthritis (age 15.6 yrs; Dz duration 7.2 yrs, 43% oligo-, 26% polyarthritis): 30% reported suicidal thoughts, 19% mod-severe depressive/anxious Sxs (moreso in Females OR 2.33) https://t.co/THW1IMqZpa https://t.co/IU2Kr3efYj
Dr. John Cush @RheumNow( View Tweet )
Seasonal Pathogens and Henoch-Schönlein Purpura
Epidemiologic studies of Henoch-Schönlein purpura (HSP) have suggested seasonal variation in occurrence rates (higher from September-April, lower in June-August), suggesting a role for infectious triggers. The importance of infection was recently shown with nonpharmaceutical interventions (
Read Article
Higher Rates of Childlessness in Rheumatic Diseases
A large Finnish population study shows that several rheumatic diseases may impair reproduction and pregnancy outcomes, with significantly higher rates of childlessness or fewer children overall for women.
A nationwide cohort study of 5 339 804 Finnish citizens, born 1964–1984,
MMWR: Vaccination and Multisystem Inflammatory Syndrome in Children
MIS-C is a rare but serious condition typically occurring 2–6 weeks after SARS-CoV-2 infection and characterized by fever and multiorgan involvement.
https://t.co/PN2MPQxqSR https://t.co/eIzB4pjner
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
